Literature DB >> 11055823

Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis.

T Shimizu1, Y Tomita, K Son, S Nishinarita, S Sawada, T Horie.   

Abstract

The aim of the study was, to examine the relationship between serum levels of soluble tumour necrosis factor receptors (sTNF-R) and the gene expression of two types of receptor for TNF (TNF-R), a 55 a receptor (TNF-R1) and a 75 kDa receptor (TNF-R2), bloodin peripheral mononuclear cells (PBMC) from patients with polymyositis and dermatomyositis (PM/DM). Soluble tumour necrosis factor receptor 1 (sTNF-R1) and soluble tumour necrosis factor receptor 2 (sTNF-R2) levels in sera from patients were measured by enzyme-linked immunosorbent assay. Expression of TNF-R1 and TNF-R2 mRNAs in PBMC was analysed by Northern blotting. Serum sTNF-R1 and sTNF-R2 levels were elevated significantly in 25 patients with active-stage PM/DM, compared to those in 18 patients with inactive-stage PM/DM and 32 normal controls. Serum concentrations of sTNF-R1 and sTNF-R2 were correlated with PM/DM disease activity. TNF-R1 gene expression was enhanced in freshly isolated PBMC from patients with active-stage PM/DM. In contrast, TNF-R2 mRNA was expressed constitutively in patients with active-stage PM/DM and in normal controls. The expression of TNF-R1 and TNF-R2 mRNAs in PBMC and elevation of their soluble forms in the sera of patients with active-stage PM/DM suggest increased proteolytic cleavage of cell surface TNF-R from PBMC in patients with active-stage PM/DM, and that sTNF-R may regulate TNF-alpha-mediated muscle fibre damage in PM/DM.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11055823     DOI: 10.1007/s100670070027

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  14 in total

1.  Tumor necrosis factor inhibitor-associated dermatomyositis.

Authors:  Rachel Klein; Misha Rosenbach; Ellen J Kim; Brian Kim; Victoria P Werth; Jonathan Dunham
Journal:  Arch Dermatol       Date:  2010-07

2.  A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis.

Authors:  Adam Schiffenbauer; Megha Garg; Christine Castro; Angelina Pokrovnichka; Galen Joe; Joseph Shrader; Imelda Victoria Cabalar; Sara Faghihi-Kashani; Michael O Harris-Love; Paul H Plotz; Frederick W Miller; Mark Gourley
Journal:  Semin Arthritis Rheum       Date:  2017-10-16       Impact factor: 5.532

3.  Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with adalimumab.

Authors:  Jin-Kyoung Park; Han-Gyul Yoo; Dae-Seon Ahn; Hyun-Soon Jeon; Wan-Hee Yoo
Journal:  Rheumatol Int       Date:  2011-11-17       Impact factor: 2.631

Review 4.  Targeted immunotherapy trials for idiopathic inflammatory myopathies.

Authors:  Joerg-Patrick Stübgen
Journal:  J Neurol       Date:  2012-06-30       Impact factor: 4.849

Review 5.  Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies.

Authors:  Namita A Goyal; Tahseen Mozaffar
Journal:  Curr Treat Options Neurol       Date:  2018-07-23       Impact factor: 3.598

Review 6.  The assessment and importance of disease activity versus disease damage in patients with inflammatory myopathy.

Authors:  Shabina M Sultan
Journal:  Curr Rheumatol Rep       Date:  2003-12       Impact factor: 4.592

7.  Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients.

Authors:  P Efthimiou; S Schwartzman; L J Kagen
Journal:  Ann Rheum Dis       Date:  2006-02-13       Impact factor: 19.103

Review 8.  Immunotherapies for Immune-Mediated Myopathies: A Current Perspective.

Authors:  Merrilee Needham; Frank L Mastaglia
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

9.  Tumor necrosis factor α release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients.

Authors:  Adam S Nabatian; Muhammad M Bashir; Maria Wysocka; Meena Sharma; Victoria P Werth
Journal:  Arthritis Res Ther       Date:  2012-01-04       Impact factor: 5.156

10.  Treatment of early and refractory dermatomyositis with infliximab: a report of two cases.

Authors:  Sylvia Dold; Maria E Justiniano; Javier Marquez; Luis R Espinoza
Journal:  Clin Rheumatol       Date:  2006-05-31       Impact factor: 3.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.